The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Drug repurposing and human parasitic protozoan diseases
Open accessAbstract
Parasitic diseases have an enormous health, social and economic impact and are a particular problem in tropical regions of the world. Diseases caused by protozoa and helminths, such as malaria and schistosomiasis, are the cause of most parasite related morbidity and mortality, with an estimated 1.1 million combined deaths annually. The global burden of these diseases is exacerbated by the lack of licensed vaccines, making safe and effective drugs vital to their prevention and treatment. Unfortunately, where drugs are available, their usefulness is being increasingly threatened by parasite drug resistance. The need for new drugs drives antiparasitic drug discovery research globally and requires a range of innovative strategies to ensure a sustainable pipeline of lead compounds. In this review we discuss one of these approaches, drug repurposing or repositioning, with a focus on major human parasitic protozoan diseases such as malaria, trypanosomiasis, toxoplasmosis, cryptosporidiosis and leishmaniasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Self-citationMurray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
Self-citationHiggins, S. M. F., Macken, A. P., Cullen, W., Saunders, J., Dunne, C. P., & O’Gorman, C. S. (2013) · PubMed · doi:10.34961/9953 · Cited by 4,806
Kotloff, K. L., Nataro, J. P., Blackwelder, W. C., Nasrin, D., Farag, T. H., Panchalingam, S., Wu, Y., Sow, S. O., Sur, D., Breiman, R. F., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60844-2 · Cited by 3,560 · cited 1×
“…study investigating the cause and effect of diarrhoea in children (under 5 years) residing in four African and three Asian study sites identified cryptospo-ridiosis as the second most common infection in infants with infection associated with death in toddlers (12–23 months) (Kotloff et al., 2013).”
Artemisinin Resistance in Plasmodium falciparum Malaria
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808859 · Cited by 3,424
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Montoya, J., & Liesenfeld, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16412-x · Cited by 3,232
Carbonic anhydrases: novel therapeutic applications for inhibitors and activators
Supuran, C. T. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2467 · Cited by 3,192
DrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861
Qinghaosu (Artemisinin): an Antimalarial Drug from China
Klayman, D. L. (1985) · Science · doi:10.1126/science.3887571 · Cited by 2,186
A molecular marker of artemisinin-resistant Plasmodium falciparum malaria
Ariey, F., Witkowski, B., Amaratunga, C., Beghain, J., Langlois, A.-C., Khim, N., Kim, S., Duru, V., Bouchier, C., Ma, L., et al. (2014) · Nature · doi:10.1038/nature12876 · Cited by 2,090
Epidemiology of and Diagnostic Strategies for Toxoplasmosis
Robert-Gangneux, F., & Dardé, M.-L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05013-11 · Cited by 1,815
The ChEMBL bioactivity database: an update
Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1031 · Cited by 1,492
Global malaria mortality between 1980 and 2010: a systematic analysis
Murray, C. J., Rosenfeld, L. C., Lim, S. S., Andrews, K. G., Foreman, K. J., Haring, D., Fullman, N., Naghavi, M., Lozano, R., & Lopez, A. D. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60034-8 · Cited by 1,452 · cited 7×
“They also threaten the lives of billions world-wide and are associated with significant morbidity and large economic impacts (World Health Organization, 2010b; Murray et al., 2012b).”
InfluentialSelf-citationSupuran, C. T., Scozzafava, A., & Casini, A. (2003) · Medicinal Research Reviews · doi:10.1002/med.10025 · Cited by 1,449
The Genome of the Kinetoplastid Parasite, Leishmania major
Ivens, A. C., Peacock, C. S., Worthey, E. A., Murphy, L., Aggarwal, G., Berriman, M., Sisk, E., Rajandream, M.-A., Adlem, E., Aert, R., et al. (2005) · Science · doi:10.1126/science.1112680 · Cited by 1,346
Toxoplasmic Encephalitis in AIDS
Luft, B. J., & Remington, J. S. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/15.2.211 · Cited by 1,287
PubChem: Integrated Platform of Small Molecules and Biological Activities
(2008) · Annual Reports in Computational Chemistry · doi:10.1016/s1574-1400(08)00012-1 · Cited by 1,263
Cook, A. J. C. (2000) · BMJ · doi:10.1136/bmj.321.7254.142 · Cited by 1,016
Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria
Achan, J., Talisuna, A. O., Erhart, A., Yeka, A., Tibenderana, J. K., Baliraine, F. N., Rosenthal, P. J., & D'Alessandro, U. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-144 · Cited by 1,007
Thousands of chemical starting points for antimalarial lead identification
Gamo, F.-J., Sanz, L. M., Vidal, J., de Cozar, C., Alvarez, E., Lavandera, J.-L., Vanderwall, D. E., Green, D. V. S., Kumar, V., Hasan, S., et al. (2010) · Nature · doi:10.1038/nature09107 · Cited by 996
Principles and Current Strategies for Targeting Autophagy for Cancer Treatment
Amaravadi, R. K., Lippincott-Schwartz, J., Yin, X.-M., Weiss, W. A., Takebe, N., Timmer, W., DiPaola, R. S., Lotze, M. T., & White, E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2634 · Cited by 897
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896
Leishmaniasis– current chemotherapy and recent advances in the search for novel drugs
Croft, S. L., & Coombs, G. H. (2003) · Trends in Parasitology · doi:10.1016/j.pt.2003.09.008 · Cited by 891
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
Dorlo, T. P. C., Balasegaram, M., Beijnen, J. H., & de Vries, P. J. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks275 · Cited by 775
Comparative genomic analysis of three Leishmania species that cause diverse human disease
Peacock, C. S., Seeger, K., Harris, D., Murphy, L., Ruiz, J. C., Quail, M. A., Peters, N., Adlem, E., Tivey, A., Aslett, M., et al. (2007) · Nature Genetics · doi:10.1038/ng2053 · Cited by 768
The global burden of congenital toxoplasmosis: a systematic review
Torgerson, P. R., & Mastroiacovo, P. (2013) · Bulletin of the World Health Organization · doi:10.2471/blt.12.111732 · Cited by 748 · cited 1×
“1D) (Torgerson and Mastroiacovo, 2013).”
In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
Ekins, S., Mestres, J., & Testa, B. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707305 · Cited by 703
Sundar, S., More, D. K., Singh, M. K., Singh, V. P., Sharma, S., Makharia, A., Kumar, P. C. K., & Murray, H. W. (2000) · Clinical Infectious Diseases · doi:10.1086/318121 · Cited by 664
Chagas disease: a new worldwide challenge
Coura, J. R., & Viñas, P. A. (2010) · Nature · doi:10.1038/nature09221 · Cited by 654
Supuran, C. T. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.05.009 · Cited by 616
Global economic burden of Chagas disease: a computational simulation model
Lee, B. Y., Bacon, K. M., Bottazzi, M. E., & Hotez, P. J. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70002-1 · Cited by 616
Hydroxychloroquine: From Malaria to Autoimmunity
Ben-Zvi, I., Kivity, S., Langevitz, P., & Shoenfeld, Y. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8243-x · Cited by 613
Chagas disease in Spain, the United States and other non-endemic countries
Gascon, J., Bern, C., & Pinazo, M.-J. (2010) · Acta Tropica · doi:10.1016/j.actatropica.2009.07.019 · Cited by 601
Drug resistance in Indian visceral leishmaniasis
Sundar, S. (2001) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.2001.00778.x · Cited by 585
Andrews, K. G., Fergus, C. A., Aregawi, M. W., Cibulskis, R. E., & Zamani, G. (2014) · Cited by 569
Self-citationSpecific chemotherapy of Chagas disease: controversies and advances
Urbina, J. A., & Docampo, R. (2003) · Trends in Parasitology · doi:10.1016/j.pt.2003.09.001 · Cited by 567
Howes, R. E., Piel, F. B., Patil, A. P., Nyangiri, O. A., Gething, P. W., Dewi, M., Hogg, M. M., Battle, K. E., Padilla, C. D., Baird, J. K., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001339 · Cited by 562
Opportunities and Challenges in Antiparasitic Drug Discovery
Pink, R., Hudson, A., Mouriès, M.-A., & Bendig, M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1824 · Cited by 545
Priotto, G., Kasparian, S., Mutombo, W., Ngouama, D., Ghorashian, S., Arnold, U., Ghabri, S., Baudin, E., Buard, V., Kazadi-Kyanza, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61117-x · Cited by 533
Innovative lead discovery strategies for tropical diseases
Nwaka, S., & Hudson, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2144 · Cited by 521
Sotelo, J., Briceño, E., & López-González, M. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00008 · Cited by 505
Neonatal Serologic Screening and Early Treatment for Congenital Toxoplasma gondii Infection
Guerina, N. G., Hsu, H.-W., Meissner, H. C., Maguire, J. H., Lynfield, R., Stechenberg, B., Abroms, I., Pasternack, M. S., Hoff, R., Eaton, R. B., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302604 · Cited by 505
Antibodies to Toxoplasma gondii in Patients With Schizophrenia: A Meta-Analysis
Torrey, E. F., Bartko, J. J., Lun, Z.-R., & Yolken, R. H. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl050 · Cited by 503
The Antiviral Activities of Artemisinin and Artesunate
Efferth, T., Romero, M. R., Wolf, D. G., Stamminger, T., Marin, J. J. G., & Marschall, M. (2008) · Clinical Infectious Diseases · doi:10.1086/591195 · Cited by 503
Guerrant, D. I., Moore, S. R., Lima, A. A., Patrick, P. D., Schorling, J. B., & Guerrant, R. L. (1999) · The American journal of tropical medicine and hygiene · doi:10.4269/ajtmh.1999.61.707 · Cited by 469
Chen, X.-M., Keithly, J. S., Paya, C. V., & LaRusso, N. F. (2002) · New England Journal of Medicine · doi:10.1056/nejmra013170 · Cited by 451
Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)
Kennedy, P. G. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70296-x · Cited by 442
Two Nonrecombining Sympatric Forms of the Human Malaria Parasite Plasmodium ovale Occur Globally
Sutherland, C. J., Tanomsing, N., Nolder, D., Oguike, M., Jennison, C., Pukrittayakamee, S., Dolecek, C., Hien, T. T., do Rosário, V. E., Arez, A. P., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/652240 · Cited by 413
Amphotericin B: time for a new “gold standard”
Saravolatz, L. D., Ostrosky-Zeichner, L., Marr, K. A., Rex, J. H., & Cohen, S. H. (2003) · Clinical Infectious Diseases · doi:10.1086/376634 · Cited by 406
Huang, R., Southall, N., Wang, Y., Yasgar, A., Shinn, P., Jadhav, A., Nguyen, D.-T., & Austin, C. P. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001862 · Cited by 401
Artemisinins: their growing importance in medicine
Krishna, S., Bustamante, L., Haynes, R. K., & Staines, H. M. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.07.004 · Cited by 388
Nunes, M. C. P., Dones, W., Morillo, C. A., Encina, J. J., & Ribeiro, A. L. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.046 · Cited by 386
Kapperud, G., Jenum, P. A., Stray-Pedersen, B., Melby, K. K., Eskild, A., & Eng, J. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008942 · Cited by 373
Dannemann, B., McCutchan, J. A., Israelski, D., Antoniskis, D., Leport, C., Luft, B., Nussbaum, J., Clumeck, N., Morlat, P., Chiu, J., et al. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-1-33 · Cited by 360
Simarro, P. P., Diarra, A., Ruiz Postigo, J. A., Franco, J. R., & Jannin, J. G. (2011) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001007 · Cited by 353
Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases
Hu, E., Dul, E., Sung, C.-M., Chen, Z., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Liu, R., Lago, A., Hofmann, G., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055541 · Cited by 347
Plasmodium Falciparum Malaria: Ultrastructure of Parasitized Erythrocytes in Cardiac Vessels
Luse, S. A., & Miller, L. H. (1971) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1971.20.655 · Cited by 345
A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target
Debnath, A., Parsonage, D., Andrade, R. M., He, C., Cobo, E. R., Hirata, K., Chen, S., García-Rivera, G., Orozco, E., Martínez, M. B., et al. (2012) · Nature Medicine · doi:10.1038/nm.2758 · Cited by 306
Meyerhoff, A. (1999) · Clinical Infectious Diseases · doi:10.1086/515085 · Cited by 295
Risk Factors for Toxoplasma Infection in Pregnancy: A Case-Control Study in France
Laurence Baril, T. A. (1999) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365549950163626 · Cited by 291
A clinical drug library screen identifies astemizole as an antimalarial agent
Chong, C. R., Chen, X., Shi, L., Liu, J. O., & Sullivan, D. J. (2006) · Nature Chemical Biology · doi:10.1038/nchembio806 · Cited by 289
Wang, Y., Suzek, T., Zhang, J., Wang, J., He, S., Cheng, T., Shoemaker, B. A., Gindulyte, A., & Bryant, S. H. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt978 · Cited by 284
Designing the next generation of medicines for malaria control and eradication
Burrows, J. N., Hooft van Huijsduijnen, R., Möhrle, J. J., Oeuvray, C., & Wells, T. N. (2013) · Malaria Journal · doi:10.1186/1475-2875-12-187 · Cited by 282
The development of drugs for treatment of sleeping sickness: a historical review
Steverding, D. (2010) · Parasites & Vectors · doi:10.1186/1756-3305-3-15 · Cited by 274
Flegr, J., Havlícek, J., Kodym, P., Malý, M., & Smahel, Z. (2002) · BMC Infectious Diseases · doi:10.1186/1471-2334-2-11 · Cited by 263
Leishmaniasis: an update of current pharmacotherapy
Sundar, S., & Chakravarty, J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.755515 · Cited by 261
Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story
Baker, N., de Koning, H. P., Mäser, P., & Horn, D. (2013) · Trends in Parasitology · doi:10.1016/j.pt.2012.12.005 · Cited by 244
Antiparasitic Agent Atovaquone
Baggish, A. L., & Hill, D. R. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1163-1173.2002 · Cited by 243
Eflornithine for the treatment of human African trypanosomiasis
Burri, C., & Brun, R. (2003) · Parasitology Research · doi:10.1007/s00436-002-0766-5 · Cited by 227
Tan, K. R., Magill, A. J., Parise, M. E., & Arguin, P. M. (2011) · The American Society of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2011.10-0285 · Cited by 227
PROMISCUOUS: a database for network-based drug-repositioning
von Eichborn, J., Murgueitio, M. S., Dunkel, M., Koerner, S., Bourne, P. E., & Preissner, R. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1037 · Cited by 225
Araujo, F. G., Huskinson, J., & Remington, J. S. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.2.293 · Cited by 220
Liposomal amphotericin B and leishmaniasis: Dose and response
Sundar, S., & Chakravarty, J. (2010) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.62886 · Cited by 217
The continuing problem of human African trypanosomiasis (sleeping sickness)
Kennedy, P. G. E. (2008) · Annals of Neurology · doi:10.1002/ana.21429 · Cited by 212
Congenital toxoplasmosis—prenatal aspects of Toxoplasma gondii infection
Rorman, E., Zamir, C. S., Rilkis, I., & Ben-David, H. (2006) · Reproductive Toxicology · doi:10.1016/j.reprotox.2005.10.006 · Cited by 209
The phenomenon of treatment failures in Human African Trypanosomiasis
Brun, R., Schumacher, R., Schmid, C., Kunz, C., & Burri, C. (2001) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.2001.00775.x · Cited by 187
Prevention and treatment of cryptosporidiosis in immunocompromised patients
Abubakar, I. I., Aliyu, S. H., Arumugam, C., Hunter, P. R., & Usman, N. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004932.pub2 · Cited by 187
A Molecular Mechanism for Eflornithine Resistance in African Trypanosomes
Vincent, I. M., Creek, D., Watson, D. G., Kamleh, M. A., Woods, D. J., Wong, P. E., Burchmore, R. J. S., & Barrett, M. P. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001204 · Cited by 184
Randomized Trial of Prolonged Chloroquine Therapy in Advanced Pulmonary Sarcoidosis
BALTZAN, M., MEHTA, S., KIRKHAM, T. H., & COSIO, M. G. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.1.9809024 · Cited by 183
Drug discovery and development for neglected diseases: the DNDi model
Ioset, J.-R., & Chatelain (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s16381 · Cited by 182
Berman, J. D., Badaró, R. J. D. S., Thakur, C. P., Wasunna, K. M., Behbehani, K., Davidson, R. N., Kuzoe, F. A. S., Pang, L. W., Weerasuriya, K., & Bryceson, A. D. M. (1998) · Europe PMC (PubMed Central) · Cited by 171
Nitazoxanide: a new broad spectrum antiparasitic agent
White Jr, A. C. (2004) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2.1.43 · Cited by 169
The global pipeline of new medicines for the control and elimination of malaria
Anthony, M. P., Burrows, J. N., Duparc, S., JMoehrle, J., & Wells, T. N. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-316 · Cited by 167
Recent Advances in the Development of Polyamine Analogues as Antitumor Agents
Casero, R. A., & Woster, P. M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900187v · Cited by 166
HDAC inhibitors in parasitic diseases
Andrews, K. T., Haque, A., & Jones, M. K. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.97 · Cited by 161
Self-citationWhat will work: fighting climate change with renewable energy, not nuclear power
(2012) · Choice Reviews Online · doi:10.5860/choice.49-6310 · Cited by 160
Nikolskaia, O. V., de A. Lima, A. P. C., Kim, Y. V., Lonsdale-Eccles, J. D., Fukuma, T., Scharfstein, J., & Grab, D. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27798 · Cited by 160
TDR Targets: a chemogenomics resource for neglected diseases
Magariños, M. P., Carmona, S. J., Crowther, G. J., Ralph, S. A., Roos, D. S., Shanmugam, D., Voorhis, W. C. V., & Agüero, F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr1053 · Cited by 147
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds
Derbyshire, E. R., Prudêncio, M., Mota, M. M., & Clardy, J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118370109 · Cited by 144
Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment
Murphy, G., Lisnevskaia, L., & Isenberg, D. A. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60889-2 · Cited by 143
Chemical Genomic Profiling for Antimalarial Therapies, Response Signatures, and Molecular Targets
Yuan, J., Cheng, K. C.-C., Johnson, R. L., Huang, R., Pattaradilokrat, S., Liu, A., Guha, R., Fidock, D. A., Inglese, J., Wellems, T. E., et al. (2011) · Science · doi:10.1126/science.1205216 · Cited by 142
Drug Resistance in Human African Trypanosomiasis
Barrett, M. P., Vincent, I. M., Burchmore, R., Kazibwe, A., & Matovu, E. (2011) · Future Microbiology · doi:10.2217/fmb.11.88 · Cited by 138
Development of Novel Drugs for Human African Trypanosomiasis
Brun, R., Don, R., Jacobs, R. T., Wang, M. Z., & Barrett, M. P. (2011) · Future Microbiology · doi:10.2217/fmb.11.44 · Cited by 138
Priotto, G., Kasparian, S., Ngouama, D., Ghorashian, S., Arnold, U., Ghabri, S., & Karunakara, U. K. (2007) · Clinical Infectious Diseases · doi:10.1086/522982 · Cited by 137
Efficacy of artemisinin in experimental visceral leishmaniasis
Sen, R., Ganguly, S., Saha, P., & Chatterjee, M. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.03.008 · Cited by 136
Artemisinins Inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense In Vitro Growth
Mishina, Y. V., Krishna, S., Haynes, R. K., & Meade, J. C. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01544-06 · Cited by 136
Xiao, S.-H. (2005) · Acta Tropica · doi:10.1016/j.actatropica.2005.07.010 · Cited by 134
Savarino, A., Lucia, M. B., Rastrelli, E., Rutella, S., Golotta, C., Morra, E., Tamburrini, E., Perno, C. F., Boelaert, J. R., Sperber, K. E., et al. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200403010-00002 · Cited by 130
Bessoff, K., Sateriale, A., Lee, K. K., & Huston, C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02460-12 · Cited by 128
Searching for New Antimalarial Therapeutics amongst Known Drugs
Weisman, J. L., Liou, A. P., Shelat, A. A., Cohen, F. E., Guy, R. K., & DeRisi, J. L. (2006) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2006.00391.x · Cited by 127
Cryptosporidiosis in developing countries
Snelling, W. J., Xiao, L., Ortega‐Pierres, G., Lowery, C. J., Moore, J. E., Rao, J. R., Smyth, S., Millar, B. C., Rooney, P. J., Matsuda, M., et al. (2007) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.360 · Cited by 122
Mel B in the Treatment of Human Trypanosomiasis
Friedheim, E. A. H. (1949) · The American journal of tropical medicine. · doi:10.4269/ajtmh.1949.s1-29.173 · Cited by 122
Discovery of Trypanocidal Compounds by Whole Cell HTS of Trypanosoma brucei
Mackey, Z. B., Baca, A. M., Mallari, J. P., Apsel, B., Shelat, A. A., Hansell, E. J., Chiang, P. K., Wolff, B. E., Guy, R. K., Williams, J. A., et al. (2006) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2006.00389.x · Cited by 121
Estimates of the duration of the early and late stage of gambiense sleeping sickness
Checchi, F., Filipe, J. A. N., Haydon, D. T., Chandramohan, D., & Chappuis, F. (2008) · BMC Infectious Diseases · doi:10.1186/1471-2334-8-16 · Cited by 116
Drug Screen Targeted at Plasmodium Liver Stages Identifies a Potent Multistage Antimalarial Drug
da Cruz, F. P., Martin, C., Buchholz, K., Lafuente-Monasterio, M. J., Rodrigues, T., Sönnichsen, B., Moreira, R., Gamo, F., Marti, M., Mota, M. M., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis184 · Cited by 114
Jaroslav Flegr, A., Klose, J., Novotná, M., Berenreiterová, M., & Havlíček, J. (2009) · BMC Infectious Diseases · doi:10.1186/1471-2334-9-72 · Cited by 113
Engel, J. C., Ang, K. K. H., Chen, S., Arkin, M. R., McKerrow, J. H., & Doyle, P. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01777-09 · Cited by 107
Pan, P., Vermelho, A. B., Rodrigues, G. C., Scozzafava, A., Tolvanen, M. E. E., Parkkila, S., Capasso, C., & Supuran, C. T. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4000616 · Cited by 106
Elazar, M., Liu, M. B., McKenna, S. A., Liu, P., Gehrig, E., Puglisi, J. D., Rossignol, J., & Glenn, J. S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.056 · Cited by 104
Management of children with infection-associated persistent diarrhea
Ochoa, T. J., Salazar‐Lindo, E., & Cleary, T. G. (2004) · Seminars in Pediatric Infectious Diseases · doi:10.1053/j.spid.2004.07.003 · Cited by 102
Iten, M., Mett, H., Evans, A., Enyaru, J., Brun, R., & Kaminsky, R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.1922 · Cited by 102
Abeloff, M. D., Rosen, S. T., Luk, G. D., Baylin, S. B., Zeltzman, M., & Sjoerdsma, A. (1986) · PubMed · Cited by 96
Syrjänen, L., Vermelho, A. B., Rodrigues, I. A., Côrte‐Real, S., Salonen, T., Pan, P., Vullo, D., Parkkila, S., Capasso, C., & Supuran, C. T. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400939k · Cited by 94
Plasmodium Kinases As Targets For New-Generation Antimalarials
Lucet, I. S., Tobin, A. B., Drewry, D. H., Wilks, A. F., & Doerig, C. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.183 · Cited by 93
Manyando, C., Njunju, E. M., D’Alessandro, U., & Geertruyden, J. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056916 · Cited by 90
Pharmacological Validation of Trypanosoma brucei Phosphodiesterases as Novel Drug Targets
de Koning, H. P., Gould, M. K., Sterk, G. J., Tenor, H., Kunz, S., Luginbuehl, E., & Seebeck, T. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir857 · Cited by 90
Krungkrai, J., Scozzafava, A., Reungprapavut, S., Krungkrai, S. R., Rattanajak, R., Kamchonwongpaisan, S., & Supuran, C. T. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.10.015 · Cited by 88
Palmer, B. S. (2007) · Seizure · doi:10.1016/j.seizure.2007.05.010 · Cited by 86
Drug repurposing programmes get lift off
Mullard, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3776 · Cited by 86
Müller, J., Sidler, D., Nachbur, U., Wastling, J. M., Brunner, T., & Hemphill, A. F. (2008) · International Journal of Cancer · doi:10.1002/ijc.23755 · Cited by 85
Traversal of human and animal trypanosomes across the blood-brain barrier
Grab, D. J., & Kennedy, P. G. E. (2008) · Journal of NeuroVirology · doi:10.1080/13550280802282934 · Cited by 83
Hotez, P. J. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.024 · Cited by 77
Güzel-Akdemir, Ö., Akdemir, A., Pan, P., Vermelho, A. B., Parkkila, S., Scozzafava, A., Capasso, C., & Supuran, C. T. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400418p · Cited by 76
Patel, G., Karver, C. E., Behera, R., Guyett, P. J., Sullenberger, C., Edwards, P., Roncal, N. E., Mensa‐Wilmot, K., & Pollastri, M. P. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400349k · Cited by 75
Smorenburg, C. H., Seynaeve, C., Bontenbal, M., Planting, A. S. T., SINDERMANN, H., & Verweij, J. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200011000-00006 · Cited by 73
Rieckmann, K. H., Powell, R. D., McNamara, J. V., Willerson, D., Kass, L., Frischer, H., & Carson, P. E. (1971) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1971.20.811 · Cited by 73
Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment
Burri, C., & Keiser, J. (2001) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.2001.00725.x · Cited by 71
Abdulla, S., & Sagara, I. (2009) · Malaria Journal · doi:10.1186/1475-2875-8-s1-s7 · Cited by 68
Chemotherapy for second-stage Human African trypanosomiasis
Lutje, V., Seixas, J., & Kennedy, A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006201.pub3 · Cited by 67
Advances in sleeping sickness therapy.
Nieuwenhove, S. V. (1992) · PubMed · Cited by 66
Open label extension studies: research or marketing?
Taylor, G. J., & Wainwright, P. (2005) · BMJ · doi:10.1136/bmj.331.7516.572 · Cited by 62
Chlorproguanil‐dapsone (LAPDAP) for uncomplicated falciparum malaria
Winstanley, P. (2001) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.2001.00751.x · Cited by 58
Artemisinin resistance is a clear and present danger
Dondorp, A. M., & Ringwald, P. (2013) · Trends in Parasitology · doi:10.1016/j.pt.2013.05.005 · Cited by 57
Abdulla, S., Salim, N., Machera, F., Kamata, R., Juma, O. A., Shomari, M., Kubhoja, S. D., Mohammed, A., Mwangoka, G., Aebi, T., et al. (2013) · Malaria Journal · doi:10.1186/1475-2875-12-11 · Cited by 56
Miller, L. H., Glew, R. H., Wyler, D. J., Howard, W. A., Collins, W. E., Contacos, P. G., & Neva, F. A. (1974) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1974.23.565 · Cited by 55
Fan-Minogue, H., Bodapati, S., Solow-Cordero, D. E., Fan, A. C., Paulmurugan, R., Massoud, T. F., Felsher, D. W., & Gambhir, S. S. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1243 · Cited by 53
Hickman, J. G., Huber, F., & Palmisano, M. (2001) · Current Medical Research and Opinion · doi:10.1185/030079901750176735 · Cited by 52
Ochiana, S. O., Pandarinath, V., Wang, Z., Kapoor, R., Ondrechen, M. J., Ruben, L., & Pollastri, M. P. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.07.038 · Cited by 49
The efficacy of benzimidazole drugs against Plasmodium falciparum in vitro
Skinner‐Adams, T. S., Davis, T. M. E., Manning, L. S., & Johnston, W. A. (1997) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(97)90035-3 · Cited by 48
Self-citationO’Brien, Z., & Moghaddam, M. F. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.834046 · Cited by 48
Katiyar, S., Kufareva, I., Behera, R., Thomas, S. M., Ogata, Y., Pollastri, M. P., Abagyan, R. A., & Mensa‐Wilmot, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056150 · Cited by 46
Santo, N. D., & Ehrisman, J. A. (2013) · Cancers · doi:10.3390/cancers5031163 · Cited by 46
Protein Kinases as Potential Targets for Novel Anti-Schistosomal Strategies
Beckmann, S., Leutner, S., Gouignard, N., Dissous, C., & Grevelding, C. G. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212801327310 · Cited by 45
Antimalarial activity of compounds comprising a primary benzene sulfonamide fragment
Andrews, K. T., Fisher, G. M., Sumanadasa, S. D. M., Skinner‐Adams, T. S., Moeker, J., Lopez, M., & Poulsen, S. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.09.015 · Cited by 43
Self-citationIs the Tide Turning for New Malaria Medicines?
Wells, T. N. C. (2010) · Science · doi:10.1126/science.1194923 · Cited by 39
Artemisinin derivatives: a patent review (2006 – present)
Njuguna, N. M., Ongarora, D. S. B., & Chibale, K. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.724063 · Cited by 34
Vaniqa--eflornithine 13.9% cream.
Shapiro, J., & Lui, H. (2001) · PubMed · Cited by 33
Kelly, J. M., Taylor, M. C., Horn, D., Loža, E., Kalvinsh, I., & Björkling, F. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.072 · Cited by 33
Goodhew, E. B., & Secor, W. E. (2013) · Sexually Transmitted Infections · doi:10.1136/sextrans-2013-051032 · Cited by 32
Drug repurposing: mining protozoan proteomes for targets of known bioactive compounds
Sateriale, A., Bessoff, K. E., Sarkar, I. N., & Huston, C. D. (2013) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2013-001700 · Cited by 32
Mesquita, J. T., Tempone, A. G., & Reimão, J. Q. (2013) · Acta Tropica · doi:10.1016/j.actatropica.2013.11.003 · Cited by 31
Could pharma open its drug freezers?
Mullard, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3473 · Cited by 30
Ogutu, B. R. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.771167 · Cited by 25
Experience with nifurtimox in chronic Chagas' infection. Preliminary report.
Dh, W., & Rw, R. (1972) · PubMed · Cited by 24
Lupus anticoagulant in the elderly may be associated with both quinine and quinidine usage
Bird, M., O’Neill, A. I., Buchanan, R. R. C., Ibrahim, K. M. A., & Parkin, J. D. (1995) · Pathology · doi:10.1080/00313029500169742 · Cited by 22
Mebendazole in parasitic infections other than those caused by soil-transmitted helminths
Cañete, R., Escobedo, A. A., Almirall, P., González, M. E., Brito, K., & Cimerman, S. (2009) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/j.trstmh.2008.11.029 · Cited by 22
Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection
Brouwers, J., Vermeire, K., Schols, D., & Augustijns, P. (2008) · Virology · doi:10.1016/j.virol.2008.06.005 · Cited by 21
Infections of the Developing World
Murthy, S., Keystone, J. S., & Kissoon, N. “. (2013) · Critical Care Clinics · doi:10.1016/j.ccc.2013.03.005 · Cited by 15
Cited by
In silico methods for drug repurposing and pharmacology
Hodos, R. A., Kidd, B. A., Shameer, K., Readhead, B. P., & Dudley, J. T. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1337 · Cited by 326
Metadata
- Authors
- Andrews, K. T., Fisher, G., & Skinner-Adams, T. S.
- Venue
- International Journal for Parasitology: Drugs and Drug Resistance
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 4
- Issue
- 2
- Pages
- 95-111
- ISSN
- 2211-3207 (ISSN-L)
- OpenAlex
- W2146071910
- Cited by
- 383
- References
- 159
- FWCI
- 32.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.